预约演示
更新于：2025-09-01
Cefotiam Hydrochloride
盐酸头孢替安
更新于：2025-09-01
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H25Cl2N9O4S3 |
InChIKeyBWRRTAXZCKVRON-DGPOFWGLSA-N |
CAS号66309-69-1 |
关联
3
项与 盐酸头孢替安 相关的临床试验NCT03045783
Efficacy and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices: A Multicenter Randomized Controlled Trial
NCT02693951
Efficiency and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices: A Randomized Controlled Trial
JPRN-UMIN000001351
Open-label randomized comparative study of cefotiam vs. ampicillin/sulbactam in adults with mild to moderate community-acquired pneumonia - Comparative study of cefotiam vs. ampicillin/sulbactam in adult community-acquired pneumonia
100 项与 盐酸头孢替安 相关的临床结果
登录后查看更多信息
100 项与 盐酸头孢替安 相关的转化医学
登录后查看更多信息
100 项与 盐酸头孢替安 相关的专利（医药）
登录后查看更多信息
1,011
项与 盐酸头孢替安 相关的文献（医药）2025-09-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Incidence of and risk factors for side effects associated with antibiotic treatment for pneumonia
Article
作者: Tanabe, Naoya ; Oi, Issei ; Yasutomo, Yoshiro ; Kadowaki, Seizo ; Konishi, Satoshi ; Hamao, Nobuyoshi ; Hirai, Toyohiro ; Ito, Isao
PURPOSE:
To determine the incidence of side effects associated with beta-lactam antibiotics commonly used in pneumonia treatment and the risk factors for each side effect.
METHODS:
Patients with community-acquired or healthcare-associated pneumonia were prospectively enrolled between June 2002 and December 2012. Patients were administered with beta-lactam antibiotics in the treatment of pneumonia. All side effects observed during the antibiotic treatment were recorded. Multivariate analysis was performed to identify independent risk factors for each side effect.
RESULTS:
A total of 1162 patients were enrolled in this study. The antibiotics used for treatment were ampicillin/sulbactam in 362, piperacillin/tazobactam in 111, cefotiam in 89, ceftriaxone in 140, cefepime in 130, imipenem/cilastatin in 110, meropenem in 97, and others in 123 cases. Diarrhea, elevated liver enzyme levels, and skin rash were observed in 174 (15.0 %), 52 (4.5 %), and 28 (2.4 %) patients, respectively. In multivariate analysis, female sex (p < 0.05) and use of either piperacillin/tazobactam (p < 0.05), cefepime (p < 0.05), or imipenem/cilastatin (p < 0.05) were significantly associated with diarrhea. Use of cefotiam (p < 0.05) or meropenem (p < 0.05) were significantly associated with elevated liver enzyme levels. No significant risk factors were found for skin rashes.
CONCLUSION:
Broad-spectrum antibiotics tended to cause diarrhea more frequently. The use of cefotiam and meropenem was associated with increased liver enzyme levels.
2025-09-01TOXICON
Identification of effective inhibitors against epsilon toxin (ETX) of Clostridium perfringens: Virtual screening and molecular dynamics simulation
Article
作者: Khaleghi, Sepideh ; Bayazian, Gholamreza ; Javaherdehi, Atefe Panahipoor ; Hashemi, Zahra Sadat
In spite of the potential for toxicity in humans, no therapeutics are approved against Epsilon toxin (ETX) for human use. Therefore, finding effective inhibitors for this toxin has garnered a lot of attention. In this regard, we performed an in silico study to find effective inhibitors against this toxin. To this end, the structure of ETX and an experimentally approved ETX inhibitor were prepared and docked as a control interaction and used for the determination of the binding site. An approved library of small molecules was obtained from the DrugBank database and prepared for virtual screening via size filtering and the addition of conformations. The top five molecules with the highest binding energy were used to draw their 2D interaction plots against ETX. A 100 ns MD simulation was performed on the Antrafenine-ETX complex as the best result of the screening stage in comparison to the control complex. The obtained results showed that among the 3849 molecules (which were analyzed by virtual screening), Cefotiam, Antrafenine, Ferric Derisomaltose, Mupirocin, and Salmeterol had the highest binding energies (binding energies respectively calculated to be -5.6, -5.8, -4.9, -4.9, and -4.6 kcal/mol). The 2D interaction plots also showed that the screened molecules had stronger interacting bonds with the ETX protein. MD simulations showed that the Antrafenine-ETX complex has a similar RMSD plot to the control complex, while its RMSF, hydrogen bond, and GR plots show better results for the Antrafenine-ETX complex. In light of these results, Antrafenine could be the best choice for ETX inhibition regarding strength, while based on the route of administration and drug applications, Cefotiam could also be considered for ETX inhibition. It seems that despite the promising results of the performed in silico studies, further empirical pieces of evidence would strengthen these conclusions in future studies.
2025-05-01Journal of Global Antimicrobial Resistance
Combined dual β-lactams and diazabicyclooctane β-lactamase inhibitor is highly effective against Mycobacterium abscessus species in vitro
Article
作者: Misawa, Kana ; Kashimura, Shoko ; Nishimura, Tomoyasu ; Shimamura, Rina ; Enoki, Yuki ; Yoshikawa, Maiko ; Taguchi, Kazuaki ; Hasegawa, Naoki ; Matsumoto, Kazuaki
OBJECTIVE:
Mycobacterium abscessus pulmonary disease is a refractory infectious disease. Developing an effective treatment is urgent as the number of patients infected with M. abscessus species (MABS) is increasing worldwide. We previously reported that nacubactam, a diazabicyclooctane (DBO) β-lactamase inhibitor, could inhibit MABS β-lactamase. Few reports have indicated that dual β-lactams are effective with a DBO β-lactamase inhibitor against MABS. The objective of this study was to determine which dual β-lactams have high antibacterial activity against MABS in the presence and absence of nacubactam.
METHODS:
Antimicrobial susceptibility tests were conducted through a checkerboard assay of 27 β-lactams using the broth microdilution method for three subspecies-type strains and 20 clinical isolates of MABS. The number of intracellular and extracellular bacteria was measured using human macrophages infected with M. abscessus treated with effective combinations confirmed in susceptibility tests.
RESULTS:
In antimicrobial susceptibility tests, 91 combinations of dual β-lactams with nacubactam exhibited synergistic effects on M. abscessus JCM13569. Among them, the combination of cefazolin, cefotiam, cefoxitin, or cefuroxime with imipenem and nacubactam exhibited highly synergistic effects, resulting in low MICs against MABS clinical isolates. Without nacubactam, the combination of imipenem and cefoxitin showed the lowest MIC. In experiments using human macrophages infected with M. abscessus, these dual β-lactam combinations reduced the number of intracellular and extracellular bacteria compared with those of single β-lactams.
CONCLUSIONS:
The combination of cefazolin, cefotiam, cefoxitin, or cefuroxime with imipenem and nacubactam was highly effective against MABS. Without nacubactam, the combination of cefoxitin and imipenem was effective.
100 项与 盐酸头孢替安 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌感染 | 美国 | 1988-12-30 | |
| 急性支气管炎 | 日本 | 1981-02-01 | |
| 急性支气管炎 | 日本 | 1981-02-01 | |
| 子宫附件疾病 | 日本 | 1981-02-01 | |
| 子宫附件疾病 | 日本 | 1981-02-01 | |
| 关节炎 | 日本 | 1981-02-01 | |
| 关节炎 | 日本 | 1981-02-01 | |
| 烧伤 | 日本 | 1981-02-01 | |
| 烧伤 | 日本 | 1981-02-01 | |
| 胆管炎 | 日本 | 1981-02-01 | |
| 胆管炎 | 日本 | 1981-02-01 | |
| 胆囊炎 | 日本 | 1981-02-01 | |
| 胆囊炎 | 日本 | 1981-02-01 | |
| 膀胱炎 | 日本 | 1981-02-01 | |
| 膀胱炎 | 日本 | 1981-02-01 | |
| 纤维肌痛 | 日本 | 1981-02-01 | |
| 纤维肌痛 | 日本 | 1981-02-01 | |
| 出血性败血症 | 日本 | 1981-02-01 | |
| 出血性败血症 | 日本 | 1981-02-01 | |
| 子宫内感染 | 日本 | 1981-02-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿道感染 | 临床1期 | 中国 | 2017-06-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用